FindTrial
Sign In

Exploring the risk factors of abnormal lipid metabolism induced by valproic acid in children with epilepsy and its effect on liver function

Exploring the risk factors of abnormal lipid metabolism induced by valproic acid in children with epilepsy and its effect on liver function

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077071
Enrollment
Unknown
Registered
2023-10-27
Start date
2023-10-31
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy

Interventions

epilepsy group:None

Sponsors

The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: (1) Age: 0-18 years old; (2) The diagnostic criteria of epilepsy were in accordance with the 1981 classification of International League Against Epilepsy and epilepsy syndrome; (3) Complete data of plasma concentration, basic clinical characteristics and biochemical indicators of the children; (4) no endocrine diseases and serious liver and kidney diseases before admission; (5) no use of drugs affecting lipid metabolism or history of abnormal lipid metabolism; (6) natural eating stat

Exclusion criteria

Exclusion criteria: (1) Severe liver and kidney diseases or endocrine diseases or dyslipidemia at admission; (2) Children with no or incomplete laboratory test results; (3) Smoking and drinking.

Design outcomes

Primary

MeasureTime frame
Blood lipid parameters;Liver function parameters;Blood routine examination;Plasma concentration;—

Countries

China

Contacts

Public ContactCai Hualin

The Second Xiangya Hospital, Central South University

hualincai@csu.edu.cn+86 137 5508 7574

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026